Statin intolerance & lipid-lowering escalation
Managing statin side effects · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
True statin intolerance is uncommon; most muscle symptoms are not caused by the statin on rechallenge. A structured approach distinguishes genuine intolerance from nocebo effect and uses alternative agents to still reach LDL-C goals.
Red flags
- CK >10x upper limit of normal
- Dark urine or marked weakness (rhabdomyolysis)
- Muscle symptoms with acute kidney injury
- Jaundice or marked transaminase rise
- Symptoms persisting after full statin washout (seek alternative cause)
Assessment
Differential diagnosis
- Nocebo/drug-aware muscle symptoms
- Vitamin D deficiency myalgia
- Hypothyroid myopathy
- Polymyalgia rheumatica
- Drug-interaction myopathy
- True statin-associated myopathy/rhabdomyolysis
Investigations
- Creatine kinase during symptoms
- TSH to exclude hypothyroidism
- Vitamin D level
- Renal and liver function
- Review of interacting drugs (fibrates, macrolides, azoles)
- Repeat lipid profile to document control
Management
- Characterise symptoms, timing and relation to statin exposure
- Check CK and exclude secondary myopathy causes and drug interactions
- Stop the statin temporarily to assess symptom resolution if CK markedly raised
- Correct vitamin D and thyroid deficiency if present
- Rechallenge with the same or a different statin at a lower dose
- Trial intermittent dosing (e.g. alternate-day or twice-weekly rosuvastatin)
- Add ezetimibe to a low statin dose to reach target
- Use bempedoic acid in genuine intolerance
- Add a PCSK9 inhibitor or inclisiran if still above goal
- Stop the statin and seek urgent review if CK >10x ULN or rhabdomyolysis signs
- Document true intolerance only after ≥2 statins failed including low-dose rechallenge
- Reassess lipid goal attainment and cardiovascular risk
Drugs & doses
Rosuvastatin 5 mg PO twice weekly (intermittent regimen)
Atorvastatin 10 mg PO alternate days (low-dose trial)
Ezetimibe 10 mg PO OD
Bempedoic acid 180 mg PO OD
Alirocumab 75 mg SC every 2 weeks (or evolocumab 140 mg SC every 2 weeks)
Inclisiran 284 mg SC at 0, 3 months then 6-monthly
Disposition
GP or lipid clinic management; refer for PCSK9 inhibitor funding assessment or if genuinely multi-statin intolerant with high risk.
Complications & pitfalls
- Rhabdomyolysis (rare)
- Under-treated cardiovascular risk from statin avoidance
- Hepatotoxicity (very rare)
- Missed alternative myopathy diagnosis
- New-onset diabetes (small absolute risk)
Exam pearls
- Most patients tolerate a statin on blinded rechallenge — nocebo effect is dominant
- Bempedoic acid is activated only in liver, sparing muscle
- Never abandon LDL lowering — use non-statin agents to the same target
- Hydrophilic statins (rosuvastatin, pravastatin) are often better tolerated
- Correct vitamin D before declaring intolerance
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.